Premium
Afatinib for an EGFR exon 20 insertion mutation: A case report of progressive stage IV metastatic lung adenocarcinoma with 54 months’ survival
Author(s) -
Chan Raymond TszTong
Publication year - 2018
Publication title -
asia‐pacific journal of clinical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.73
H-Index - 29
eISSN - 1743-7563
pISSN - 1743-7555
DOI - 10.1111/ajco.12853
Subject(s) - afatinib , exon , medicine , stage (stratigraphy) , adenocarcinoma , oncology , lung , mutation , cancer research , epidermal growth factor receptor , gefitinib , cancer , biology , gene , genetics , paleontology
Abstract Non–small cell lung cancers (NSCLC) harboring the uncommon epidermal growth factor receptor (EGFR) exon 20 insertion mutations are generally thought to be unresponsive to EGFR‐tyrosine kinase inhibitor (TKI) therapy. Presented here is a case of stage IV NSCLC harboring an uncommon EGFR exon 20 insertion mutation that was maintained at minimal progressive disease for 54 months, with 36 months on the second‐generation TKI afatinib. Contrary to the existing literature, the patient in this case demonstrated a long, durable response to the EGFR‐TKI, which was exhibited by a long survival endpoint. This suggests that stability in clinical symptoms might be sufficient to warrant continuation of therapy.